Translated automatically – community improvements welcome.
(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-…
Dihydroergotamine is a semi-synthetic ergot alkaloid primarily used for the treatment of migraine. It acts primarily through vasoconstriction via serotonin and adrenergic receptors and modulates dopaminergic systems. Due to its complex mechanisms of action, it can cause side effects such as nausea and cardiovascular effects. The substance is used under medical supervision and should not be combined with other vasoconstrictors.
Mechanism of Action
- 5-HT1B agonist
- 5-HT1D agonist
- alpha-adrenergic agonist
Names / Identifiers
IUPAC: Dihydroergotamine
Mechanism of Action
Dihydroergotamin wirkt hauptsächlich als Agonist an Serotoninrezeptoren, insbesondere 5-HT1B und 5-HT1D, was zu einer Vasokonstriktion der intrakraniellen Blutgefäße führt.
Effects
Effects described from scientific sources. Individual experiences vary.
Dosage
Individual sensitivity varies. Not a dosage recommendation.
Duration
Risks & Warnings
Warnings
- Pregnancy
- Cardiovascular diseases
Known Risks
- medium
- Mögliche Nebenwirkungen umfassen Übelkeit, Schwindel und vasospastische Reaktionen.
Safer Use
- Start at a low dose
- Avoid polydrug use with other vasoconstrictors
Harm reduction tips do not replace medical advice.
Known Interactions
- MAO inhibitors
- Beta-blockers
This list is not exhaustive. Interactions can have unpredictable effects.
Legal Status
Not legal advice. Status may change.
Entdecken
Ähnliche Substanzen
Basierend auf Substanzklasse, Rezeptoren, Wirkmechanismen und Wirkprofil.